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Akt/PKB is a serine/threonine protein kinase that regulates cell cycle progression, apoptosis and growth factor mediated cell
survival in association with tyrosine kinase receptors. The protein is a downstream effector of erbB-2 with implications in
breast cancer progression and drug resistance in vitro. We aimed to examine the role of Akt-1 in breast cancer patients, by
determining whether the expression (Akt-1) and/or activation (pAkt) were related to prognostic markers and survival. The
expression of erbB-2, heregulin b1 and Bcl-2 was also assessed by ﬂow cytometry or immunohistochemistry. This study
comprised 93 patients, aged 550 who were treated with tamoxifen and/or goserelin. We found that pAkt was associated
with lower S-phase fraction (P=0.001) and the presence of heregulin b1-expressing stromal cells (P=0.017). Neither Akt-1 nor
pAkt was related with other factors. Tumour cells-derived heregulin b1 was found mainly in oestrogen receptor negative
(P=0.026) and node negative (P=0.005) cases. Survival analysis revealed that pAkt positive patients were more prone to
relapse with distant metastasis, independently of S-phase fraction and nodal status (multivariate analysis; P=0.004). The results
suggest that activation of Akt may have prognostic relevance in breast cancer.
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Endocrine therapy remains the most used systemic treatment in
breast cancer. The presence of oestrogen receptor (ER) is the guide
in the therapeutic decision. Complete oestrogen blockade seems to
be more effective compared with single agent endocrine treatment.
Combined therapy, involving luteinizing hormone-releasing
hormone (LHRH) analogues such as goserelin (Zoladex) and
tamoxifen has been employed to reduce oestrogen levels and to
prevent the oestrogenic activity at the cellular level (Michaud and
Buzdar, 2000). However in spite of higher response rate, tumour
resistance to endocrine treatments develops over time and constitu-
tes a critical problem (MacGregor and Jordan, 1998; Clarke et al,
2001).
Anti-oestrogen resistance may be explained by several mechan-
isms, including loss or mutation of ER, increased estradiol level,
alterations in anti-oestrogen metabolism or interactions between
growth factor receptors and ER cascades (reviewed in Clarke et
al, 2001). These mechanisms, mainly involved in cell proliferation,
may coexist with those affecting cell death. Increasing amount of
evidence indicates that the mechanisms whereby drugs such as
the LHRH analogues and tamoxifen exert the cytotoxic action also
include apoptosis (Perry et al, 1995; Imai and Tamaya, 2000).
Therefore, factors involved in the apoptotic failure may also contri-
bute to the anti-oestrogen resistance.
Recently, the phosphatidylinositol 3' kinase (PI3K)/Akt cascade,
which is the major survival pathway for many cell types, has been
related to activation of ER in vitro and with protection from
tamoxifen-induced apoptosis (Campbell et al, 2001).
Akt, also called protein kinase B (PKB), is the cellular homolo-
gue of the vAkt oncogene found in the highly transforming
retrovirus AKT8 (Ahmed et al, 1993). Human Akt exists as three
closely related isoforms: Akt-1/PKBa, Akt-2/PKBb and Akt-3/PKBg.
Akt-1 is activated by phosphorylation on two critical residues:
threonine 308 in the kinase domain and serine 473 in the C-term-
inal tail. The active protein (pAkt) is a downstream effector of the
growth factor-stimulated PI3K (Coffer et al, 1998) and may contri-
bute to the genesis of cancer by blocking programmed cell death
(Kandel and Hay, 1999).
From in vitro studies it is known that induction of cell survival
by Akt isoforms affects signalling cascades triggered by a wide
range of receptors. Platelet-derived growth factor (PDGF) (Klin-
ghoffer et al, 1996), insulin growth factor (IGF) (Duan et al,
1999), and the epidermal growth factor (EGF) family members
(Ram and Ethier, 1996; Okano et al, 2000) are among those recep-
tors. Akt-1 has been found in correlation with higher expression of
erbB-2 in a panel of breast cancer cell lines (Ahmad et al, 1999). A
recent report showed that inhibition of this pathway with a mono-
clonal antibody against erbB-2 was not restricted to cells that
overexpressed erbB-2 but also interfered with heregulin b1
(HRG)-mediated activation in cells with basal levels of the receptor
(Liu et al, 1999). The former indicates that both, overexpression of
erbB-2 and stimulation with HRG could be able to trigger this
pathway (Tan et al, 1999; Ignatoski et al, 2000).
Until the present, Akt isoforms has been found overexpressed in
several tumour types (Staal, 1987; Bellacosa et al, 1995; Cheng et al,
1996; Ruggeri et al, 1998) but the information in breast cancer is
limited. In the present study we analyzed the expression and acti-
vation of Akt-1 in relation to some factors involved in its pathway
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www.bjcancer.comas well as other tumour characteristics. We also aimed to examine
the signiﬁcance of this protein for patient’s survival after endocrine
treatment.
MATERIALS AND METHODS
Patients
This study comprized 93 breast cancer patients (35–49 years) from
the Southeast Sweden Health Care Region who underwent surgery
between 1984 and 1996. All patients were treated with tamoxifen,
goserelin or both endocrine modalities. The tumours were positive
for ER or progesterone receptor (PgR) in 96% of the cases. The
medium follow-up time among the disease-free patients was 64
months. The ﬁrst relapse appeared 20 months after surgery and
further on 22 patients (24%) relapsed with distant metastasis.
For this study we used frozen sections from tumours still available
after hormone receptor assays. The material was stored at 7708C
until used.
Determination of steroid receptors and S-phase fraction
The levels of steroid hormones were measured using the EIA assay
from Abbot (Lab. Diagnostic Division, Abbot Park, USA). Samples
with ER or PgR 50.3 fmol mg
71 DNA were considered as positive.
Likewise, DNA ﬂow cytometry was performed in clinical routine
practice to determine the S-phase fraction (SPF). A cut-off level
of 10% was used to differentiate tumours with low and high SPF
respectively. Both methods have been described previously (Sta ˚l
et al, 1992)
Flow cytometry to determine erbB-2 content
This method was previously described (Sta ˚l et al, 1994). Fixation
was carried out in 1% paraformaldehyde for 3 min. The cells were
incubated with the monoclonal antibody c-neu (Ab-2), clone 9G6
(Oncogene Science Inc., Manhasset, NY, USA) or an irrelevant
isotype control antibody (Sigma Chemical Co., St Louis, MI,
USA), both diluted in PAB at 1 mgm l
71. The secondary antibody
rabbit-anti-mouse F(ab)2 conjugated with FITC (DAKO,
Denmark) was added at a 1:50 dilution. Finally the cells were
treated with RNAse, stained with propidium iodide and analyzed
in a FACScan ﬂow cytometer (Becton Dickinson, USA). A ﬂuor-
escence index (FI) was calculated as the ratio between the
geometrical mean of the ﬂuorescence associated with the speciﬁc
antibody and the negative control. Tumours with FI 52.0 were
considered as positive.
Immunohistochemical detection
The staining procedure followed a standard protocol. Imprints
from nine tumours, otherwise frozen-sections (5 mm) were used
for this purpose. Slides were ﬁxed in acetone for 10 min at 48C;
blocked in PBS-10% swine serum (DAKO, Denmark) and incu-
bated with the primary antibodies: a mouse monoclonal
antibody, clone 124 (3.5 mgm l
71) (DAKO, Denmark) to detect
Bcl-2; a sheep polyclonal antibody (at 8 mgm l
71) against the
phosphorylated Ser residue in position 473 of human Akt-
1(Upstate Biotechnology; Lake Placid, NY, USA); and goat poly-
clonal antibodies against-HRG (at 0.5 mgm l
71) and Akt-1 (at
8 mgm l
71) respectively (Santa Cruz Biotechnology, Inc). The
negative control, in case of Bcl-2, consisted of a mouse IgG1
kappa-Mopc 21 (Sigma Aldrich, Sweden) at a concentration of
8 mgm l
71 while the polyclonal antibodies were incubated with
their respective neutralizing peptides. Incubation with primary
antibodies was performed overnight at 48C in a moisture cham-
ber. As secondary antibody a swine multi-link IgG1 anti-goat/
mouse/rabbit conjugated with biotin and diluted 1:50 was
employed, followed by streptavidin–horseradish peroxidase
(DAKO, Denmark). Positive cells were visualized with 3.3-diami-
nobenzidin hydrochloride and the nuclei were counterstained
with haematoxylin.
Scoring
Two independent observers evaluated the sections using a light
microscopy Leica DM LS (Leica Microsystems; Wetzlar, Germany).
In case of HRG, we analyzed the staining associated to malignant
cells and the surrounding stromal cells (ﬁbroblasts). Tumours were
considered positive for the stromal reaction when 10% or more
stained ﬁbroblasts were observed. In this case the imprints were
excluded for being unreliable. In the malignant population we
considered intensity (+ or ++) and frequency: (a) 0 cells; (b) 1–
10% cells; (c) 410–50% cells; and (d) 450% of the cells being
positive. The frequency and intensity were added to regroup the
variable into three categories: (1) no reaction; (2) low reaction
(1–10%/+/++ or 410–50%/+); (3) strong reaction (410–
50%/++ or staining in 450%/+/++).
For Akt-1 and pAkt, the tumours were considered positive,
independently of the frequency, when the brown colour observed
in the cytoplasm of the cells was strong and clearly different from
that of the negative control. For Bcl-2, a cut-off point of 510%
was considered on the base of previous studies (Hellemans et al,
1995; Elledge et al, 1997).
Peptide neutralization assay
Blockade with synthetic peptides tested the speciﬁcity of the
polyclonal antibodies. The highest working dilution for the anti-
bodies was established as 2 mgm l
71 in case of pAkt and
0.5 mgm l
71 in case of HRG. To be neutralized, the antibodies
were pre-incubated overnight at 48C with ﬁve and 10 times more
peptide (for pAkt and HRG respectively) in a total volume of
100 ml and centrifuged at 10000 g. Supernatants were applied
to the sections.
Statistics
The relationships between different variables were assessed by the
Chi-square test or Chi-square test for trend, when required. The
role of each variable (univariate analysis) or their joint effect
(multivariate analysis) was evaluated with Cox’s proportional
hazard regression. The multiple sample test, which is a generaliza-
tion of Gehan’s generalized Wilcoxon test, was also used to test the
signiﬁcance in the survival analysis. All the procedures are
comprised in the statistical package ‘Statistica’ (Statsoft, inc 1999
Statistica for Windows). The criterion for statistical signiﬁcance
was P50.05.
RESULTS
Association of Akt-1 and pAkt with other variables
The pattern of staining for Akt-1 is shown in Figure 1A. The
protein was expressed in 46% of the tumours without signiﬁcant
correlation with any prognostic factor. On the other hand, pAkt,
positive in 54% of the cases (Figure 1B), was positively correlated
with the presence of HRG-expressing ﬁbroblasts (P=0.017) and
inversely to the SPF (P=0.001). No association was seen with nodal
status, tumour size, ER, PgR, Bcl-2 or erbB-2 (Table 1). A moder-
ate correlation, although statistically signiﬁcant (P=0.04), was
found between Akt-1 and pAkt staining. Besides, HRG, observed
in malignant cells, was negatively associated with lymph node
status (P=0.005) and with ER (P=0.026). The controls consisting
of peptide-blocked antibodies were negative in all cases (result
not shown).
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recurrence-free survival
In univariate analysis neither HRG nor Akt-1 had prognostic value,
while pAkt positivity predicted a higher risk of developing metas-
tasis with borderline signiﬁcance (RR=2.4, 95% CI, 1.0–6.2) (see
Figure 2A). Multivariate analysis, including pAkt and traditional
prognostic factors, indicated that pAkt was an independent predic-
tor of distant recurrence (Table 2). The risk in the pAkt+ group
was higher (5.4) compared to the pAkt7 group; (P=0.004).
Besides, the risk also increased signiﬁcantly for the lymphonode
positive patients (P=0.0008) and for those with high SPF (P=0.01).
The possible phenotypes of pAkt in combination with SPF are
shown in Figure 2B. Patients with low SPF and pAkt negative
tumour had a 6 year survival rate of 93% in comparison with
47% for those with high SPF and pAkt positive phenotype. The
distant recurrence-free survival in relation to pAkt and nodal status
is shown in Figure 2C. All patients in the double negative group
(node-/pAkt-) remained alive after 6 years of follow-up while in
the node+/pAkt+ group the distant recurrence-free survival rate fell
to 59%.
DISCUSSION
As far as we know this is the ﬁrst immunohistochemical study
analyzing the expression and activation of Akt in breast tumours
in relation to other clinico–pathological variables and survival.
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Figure 1 Representative immunostaining of Akt-1 (A) (2006) and pAkt
(B) (4006), note the arrowheads indicating positive staining in the
cytoplasm of malignant cells.
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Figure 2 (A) Kaplan–Meier curves comparing survival among pAkt
negative patients in comparison with pAkt positive group (P=0.07 by
Cox proportional hazard model and P=0.03 by Gehan’s generalized Wil-
coxon test). (B) pAkt/SPF subgroups. The combined variable was scored
as: 0 (SPF-/pAkt-); 1 (SPF+/pAkt-); 2 (SPF-/pAkt+); 3 (SPF+/pAkt+). Ac-
cording to this order, the risk of developing distant recurrence increased
gradually with a rate ratio of 1.8 (Cox proportional hazard regression,
P=0.017). Distant recurrence-free survival rates at 6 years were of 93,
88, 69 and 47% respectively for each subgroup. (C) Kaplan–Meier curves
based on pAkt and nodal status. The combined variable was scored as: 0
(node-/pAkt-); 1 (node-/pAkt+); 2 (node+/pAkt-; 3 (node+/pAkt+).
According to this order, the risk of developing distant recurrence increased
gradually with a rate ratio of 2.5 (Cox proportional hazard regression
P=0.001). Distant recurrence-free survival rates at 6 years were 100, 85,
81 and 59% respectively for each subgroup. In the lymph node negative
group there were two recurrences; both belonged to pAkt+ subgroup.
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British Journal of Cancer (2002) 86(4), 540–545 ã 2002 Cancer Research UKWe aimed to examine whether this protein, found in vitro to play a
prominent role in oncogenesis (Kandel and Hay, 1999) and
possibly in tamoxifen resistance (Campbell et al, 2001), showed
the same signiﬁcance in clinical material.
In this study, Akt-1 was considered positive in 46% of the
tumours but it was not associated with any other prognostic
marker. The variable did not provide any new information regard-
ing the survival of the patients. Despite a positive correlation
between Akt-1 and the activated protein, some Akt-1 negative cases
resulted as pAkt positive. This paradox may be explained by either
different sensitivity of the antibodies or by crossreactivity of the
phospho-Akt-1 (ser473) antibody with another activated isoform
present in the tumour, like Akt-2 or Akt-3. Otherwise, the pattern
of staining with both antibodies was similar, being the phosphory-
lated protein localized to some extent to the cell membrane and
mainly observed in the cytoplasm of the malignant cells. Albeit
the activation of Akt is generally associated with its translocation
from the cytosol to the plasma membrane by virtue of its pleckstrin
homology (PH) domain (Andjelkovic et al, 1997), it is possible for
Akt lacking a PH domain to be activated without being localized to
this cell compartment (Sable et al, 1998).
As in case of Akt-1, we could not ﬁnd any signiﬁcant association
of pAkt with nodal status, tumour size, ER, PgR or Bcl-2 but we
did ﬁnd a strong negative association with SPF. Since the activation
of Akt promotes cell cycle progression by modulating the expres-
sion (Brennan et al, 1997; Muise-Helmericks et al, 1998) and
stabilization of cyclin D1 (Graff et al, 2000) and the SPF is an indi-
cator of the proliferative state of the cells, the negative association
between pAkt and SPF was unexpected. Nevertheless, an increase in
cyclin D1 does not always lead to cell cycle progression (Hiyama et
al, 1997; Mitsuuchi et al, 2000), and in some cases the expression
of cyclin D1 has been associated with low proliferative rate in clin-
ical material (Nielsen et al, 1999). Furthermore, the survival
analysis indicated that patients in the pAkt positive group tended
to have a higher risk to develop distant recurrence compared to
the negative group, and the multivariate analysis showed that pAkt
was an independent prognostic factor in addition to nodal status
and SPF. The analysis of the interaction between pAkt and SPF
revealed that a low SPF was a favourable feature only if the tumour
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 1 Akt-1 and pAkt in relation to other clinical data and tumour characteristics
Akt-17 Akt-1+ pAkt7 pAkt+
n (%) n (%) Signiﬁcance n (%) n (%) Signiﬁcance
Nodal status
7 20 (57) 15 (43) P=0.60 18 (51) 17 (49) P=0.43
+ 30 (52) 28 (48) 25 (43) 33 (57)
Tumour size
520 mm 25 (59) 17 (40) P=0.30 17 (59) 25 (41) P=0.30
520 mm 25 (49) 26 (51) 26 (51) 25 (49)
ER
7 11 (50) 11 (50) P=0.70 13 (59) 9 (41) P=0.16
+ 39 (55) 32 (45) 30 (42) 41 (58)
PgR
7 4 (57) 3 (43) P=0.85 4 (57) 3 (43) P=0.54
+ 46 (53) 40 (47) 39 (45) 47 (55)
SPF
a
510% 20 (44) 25 (56) P=0.08 15 (33) 30 (67) P=0.001
510% 23 (64) 13 (36) 25 (69) 11 (31)
erbB-2
FI52.0 48 (55) 39 (45) P=0.30 40 (46) 47 (54) P=0.80
FI52.0 2 (33) 4 (67) 3 (50) 3 (50)
Bcl-2
7 24 (62) 15 (38) P=0.20 17 (44) 22 (56) P=0.60
+ 26 (48) 28 (52) 26 (48) 28 (52)
HRGb1 malignant cells
b
No 17 (59) 12 (41) P=0.90 16 (55) 13 (45) P=0.43
Low 17 (44) 22 (56) 15 (38) 24 (62)
High 13 (59) 9 (41) 10 (45) 12 (55)
HRGb1 host cells
c
510% 31 (60) 21 (40) P=0.15 28 (78) 8 (22) P=0.017
510% 13 (43) 17 (57) 24 (52) 22 (48)
a, b, cData from 12, 3 and 11 patients respectively is missing.
Table 2 Multivariate Cox proportional hazard regression to determine
the predictive value of different variables in relation to distant recur-
rence. Data for all of the patients was available in 81 cases
Rate ratio (95% CI) Signiﬁcance
Nodal status
7 1.0
+ 13.9 (2.9763.1) P=0.008
Tumour size
520 mm 1.0
520 mm 1.5 (0.673.7) P=0.37
ER
7 1.0
+ 0.58 (0.271.9) P=0.37
PgR
7 1.0
+ 0.9 (0.275.4) P=0.93
SPF
510% 1.0
510% 3.9 (1.4710.7) P=0.01
pAkt
7 1.0
+ 5.4 (1.7717.1) P=0.004
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 540–545was in addition pAkt negative. This suggests that pAkt could be
indicative of distant relapses in spite of a low proliferative state
of the tumour, probably by promoting cell survival rather than cell
proliferation.
In a previous report, including 20 adenocarcinomas, a signiﬁ-
cant association was found between the expression of erbB-2 and
pAkt (Zhou et al, 2000). In the present study we found no signiﬁ-
cant association of erbB-2 with Akt-1 or with pAkt. We consider
that our study could be undersized to detect signiﬁcant differences,
since only 7% of the tumours overexpressed the receptor (n=6) as
expected in a sample conformed mostly by ER or PgR positive
tumours. Therefore a larger material might help to conﬁrm this
relationship but also it may be interesting to address this question
in the context of other EGF family members such as erbB-3, 4 and
EGFR.
In this study we also explored the ligand HRG. The protein can
be present in the cytoplasm of both malignant and stromal cells.
While in a previous report, the host-derived HRG correlated with
aggressive clinical behaviour (Visscher et al, 1997) we did not ﬁnd
the same result in our study. However we found a positive correla-
tion between host-derived HRG and pAkt. It is known that the
breast stroma plays an important role in breast epithelial growth
and differentiation. Besides, tumour-associated ﬁbroblasts have
been found to confer morphogenic and mitogenic induction of
epithelial cells (Shekhar et al, 2001) and to induce acceleration of
epithelial tumour growth in vivo (Camps et al, 1990) supporting
the role of host cells as source of paracrine signals that may not
only affect cell growth but also turn on survival pathways, like Akt.
On the other hand, in those tumours where HRG was found in
the malignant cells the patients less often showed evidence of
lymphonodal spread in line with the results of Bacus et al
(1994). The negative association found with ER status still could
implicate this factor with an aggressive phenotype, although the
risk to develop distant metastasis was not higher among the
patients with high expression of HRG. A possible interaction with
nodal status is not excluded since among the node positive patients
the recurrence rate tended to be higher in cases of high HRG
expression (result not shown). Nevertheless the role of HRG in vivo
remains to be explained. This factor has been associated in vitro
with induction of cell proliferation (Holmes et al, 1992; Aguilar
et al, 1999), invasion (Hijazi et al, 2000), apoptosis (Daly et al,
1997), differentiation (Peles et al, 1992; Bacus et al, 1993) and inhi-
bition of cell proliferation (Hamburger and Yoo, 1997; Xu et al,
1997).
We conclude that the activation of Akt could be a factor to
consider together with S-phase fraction and nodal status in predict-
ing distant relapses of breast cancer. However it remains to be
elucidated which isoform plays the principal role. The shorter
disease-free survival associated with the pAkt positive phenotype
in this series of endocrine treated patients, may indicate a link
between this pathway and treatment failure but further studies
based on randomized trials are needed to validate this hypothesis.
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